Skip to main content
. 2022 Jan 31;9(1):e000763. doi: 10.1136/bmjgast-2021-000763

Table 1.

Baseline characteristics, IBD phenotype and biomarkers at ASUC diagnosis

Variable N Inpatients
n=695
Ambulatory
n=69
P value
Ambulatory from diagnosis
n=15
Initially inpatient and then discharged to ambulatory
n=54
Sex F 764 50.1% (348/695) 53.3% (8/15) 38.9% (21/54) 0.27
M 764 49.9% (347/695) 46.7% (7/15) 61.1% (33/54)
Age (years) 764 37.0 (26.0–53.0) 30.0 (22.0–39.0) 44.5 (33.0–58.8) 0.02
IBD type
 UC 764 95.7% (665/695) 93.3% (14/15) 92.6% (50/54) 0.34
 IBD-U 764 4.3% (30/695) 6.7% (1/15) 7.4% (4/54)
BMI 424 24.4 (21.2–27.9) 24.0 (20.4–28.9) 24.9 (22.8–30.9) 0.31
No of comorbidities
 0 764 72.2% (502/695) 60.0% (9/15) 64.8% (35/54) 0.45
 1 764 19.3% (134/695) 26.7% (4/15) 22.2% (12/54)
 2 764 5.5% (38/695) 6.7% (1/15) 7.4% (4/54)
 >2 764 3.0% (21/695) 6.7% (1/15) 5.6% (3/54)
Years since diagnosis 722 1.0 (0.0–5.0) 1.0 (0.0–7.5) 1.5 (0.0–8.2) 0.85
UC extent
 E1—proctitis 693 8.5% (54/636) 8.3% (1/12) 4.4% (2/45) 0.53
 E2—left-sided disease 693 47.3% (301/636) 41.7% (5/12) 60.0% (27/45)
 E3—pan-colitis 693 44.2% (281/636) 50.0% (6/12) 35.6% (16/45)
Biomarkers at day 1
 Stool frequency 612 10.0 (8.0–15.0) 12.0 (10.0–14.8) 10.0 (7.0–13.5) 0.42
 CRP 704 54.0 (20.0–114.8) 40.0 (14.0–72.2) 52.5 (20.0–114.5) 0.32
 Albumin 664 35.0 (30.0–40.0) 38.0 (35.0–41.2) 37.0 (30.5–39.5) 0.39
 Haemoglobin 704 123.0 (107.0–135.5) 134.0 (113.5–144.5) 129.0 (110.0–141.0) 0.15
Most recent faecal calprotectin prior to flare (ug/g) 229 501.5 (155.8–1364.0) 390.0 (78.0–416.0) 600.0 (244.8–1234.2) 0.62

P value=Fisher’s exact test or Kruskal-Wallis test for discrete and continuous variables continuous, respectively. Discrete variables displayed % (n/N) and continuous variables median (IQR).

ASUC, acute severe colitis; BMI, body mass index; CRP, C reactive protein; IBD, inflammatory bowel disease; UC, ulcerative colitis.